A Multicenter, Randomized, Double-blind (Sponsor-unblinded), Placebo-controlled Study to Investigate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2982772 in Subjects With Moderate to Severe Rheumatoid Arthritis
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Jul 2018
At a glance
- Drugs GSK 2982772 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 21 Jun 2018 Planned End Date changed from 14 Jan 2019 to 31 Oct 2018.
- 21 Jun 2018 Planned primary completion date changed from 14 Jan 2019 to 31 Oct 2018.
- 18 Jun 2018 Status changed from recruiting to active, no longer recruiting.